Orasis Pharmaceuticals is an ophthalmic pharmaceutical company that develops eye drops for the treatment of presbyopia.
Orasis Pharmaceuticals has raised $68.0M in total funding. The most recent round was Series D. The last funding was announced in October 2024.
Orasis Pharmaceuticals's investors include Sequoia Capital, Catalio Capital Management, Maverick Ventures, Arboretum Ventures, LifeSci Venture Partners.
Orasis Pharmaceuticals is headquartered in Ponte Vedra, United States.
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company that develops eye drops for the treatment of presbyopia.
Orasis Pharmaceuticals is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orasis Pharmaceuticals — Funding & Investors." VCBacked, October 8, 2024, https://www.vcbacked.co/company/orasis-pharmaceuticals. Accessed October 30, 2026.
VCBacked. (2024). Orasis Pharmaceuticals — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/orasis-pharmaceuticals
{{cite web |title=Orasis Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/orasis-pharmaceuticals |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated